Pulmonary Medication Adherence and Health-care Use in Cystic Fibrosis
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background Poor treatment adherence is common in cystic fibrosis (CF) and may lead to worse health outcomes and greater health-care use. This study evaluated associations of adherence to pulmonary medications, age, health-care use, and cost among patients with CF. Methods Patients with CF aged ≥ 6 years were identified in a national commercial claims database. A 12-month medication possession ratio (MPR) was computed for each pulmonary medication and then averaged for a composite MPR (CMPR) for each patient. The CMPR was categorized as low ( Results Mean CMPR for the sample (N = 3,287) was 48% ± 31%. Age was inversely related to CMPR. In the concurrent year, more CF-related hospitalizations were observed among patients with low (event rate ratio [ERR], 1.35; 95% CI, 1.15-1.57) and moderate (ERR, 1.25; 95% CI, 1.05-1.48) vs high adherence; similar associations were observed for all-cause hospitalizations and CF-related and all-cause acute care use (hospitalizations + ED) in the concurrent and subsequent year. Rates of CF-related and all-cause outpatient visits did not differ by adherence. Low and moderate adherence predicted higher concurrent health-care costs by $14,211 ($5,557-$24,371) and $8,493 (-$1,691 to $19,709), respectively, compared with high adherence. Conclusions Worse adherence to pulmonary medications was associated with higher acute health-care use in a national, privately insured cohort of patients with CF. Addressing adherence may reduce avoidable health-care…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Low adherence to all treatments is associated with an increased number of pulmonary exacerbations requiring intravenous (IV) antibiotics (Eakin 2011) and hospitalisations, which incur higher healthcare costs (Quittner 2014).”
From Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis (2023) · cites this paper as Quittner 2014
Citations
Cites
Physician Communication and Patient Adherence to Treatment: A Meta-Analysis
Haskard Zolnierek, K. B., & DiMatteo, M. R. (2009) · Medical Care · doi:10.1097/mlr.0b013e31819a5acc · Cited by 2,489
Patient Adherence and Medical Treatment Outcomes: A Meta-Analysis
Robin DiMatteo, M., Giordani, P. J., Lepper, H. S., & Croghan, T. W. (2002) · Medical Care · doi:10.1097/00005650-200209000-00009 · Cited by 1,490
Interventions to Enhance Patient Adherence to Medication Prescriptions: Scientific Review
McDonald, H. P., Garg, A. X., & Haynes, R. B. (2002) · JAMA · doi:10.1001/jama.288.22.2868 · Cited by 1,176
Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Flume, P. A., O'Sullivan, B. P., Robinson, K. A., Goss, C. H., Mogayzel, P. J., Willey-Courand, D. B., Bujan, J., Finder, J., Lester, M., Quittell, L., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-664oc · Cited by 1,024
A Controlled Trial of Long-Term Inhaled Hypertonic Saline in Patients with Cystic Fibrosis
Elkins, M. R., Robinson, M., Rose, B. R., Harbour, C., Moriarty, C. P., Marks, G. B., Belousova, E. G., Xuan, W., & Bye, P. T. P. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa043900 · Cited by 862
Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health
Mogayzel, P. J., Naureckas, E. T., Robinson, K. A., Mueller, G., Hadjiliadis, D., Hoag, J. B., Lubsch, L., Hazle, L., Sabadosa, K., Marshall, B., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201207-1160oe · Cited by 615
Kahana, S., Drotar, D., & Frazier, T. (2008) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsm128 · Cited by 334
How patient cost-sharing trends affect adherence and outcomes: a literature review.
Eaddy, M. T., Cook, C. L., O'Day, K., Burch, S. P., & Cantrell, C. R. (2012) · Europe PMC (PubMed Central) · Cited by 329
Barriers to Treatment Adherence for Children with Cystic Fibrosis and Asthma: What Gets in the Way?
Modi, A. C., & Quittner, A. L. (2006) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsj096 · Cited by 301
Self-citationA multi-method assessment of treatment adherence for children with cystic fibrosis
Modi, A. C., Lim, C. S., Yu, N., Geller, D., Wagner, M. H., & Quittner, A. L. (2006) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2006.03.002 · Cited by 265
Self-citation
Research works printed but not linked: 2
- Pressler, 2011, Aztreonam for inhalation solution, an aerosolized antibiotic for the treatment of pseudomonal airway infection in patients with cystic fibrosis, US Res Dis, 7, 107
- Quinn, 2004, Measuring, predicting and improving adherence to inhalation in patients with CF: a randomised controlled study of motivational interviewing [abstract], Pediatr Pulmonol, 38, 360
Cited by
Economic impact of medication non-adherence by disease groups: a systematic review
Cutler, R. L., Fernandez-Llimos, F., Frommer, M., Benrimoj, C., & Garcia-Cardenas, V. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-016982 · Cited by 900
Ratjen, F., Bell, S. C., Rowe, S. M., Goss, C. H., Quittner, A. L., & Bush, A. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.10 · Cited by 546
Self-citationCFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine
Lopes-Pacheco, M. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01662 · Cited by 535
Quittner, A. L., Goldbeck, L., Abbott, J., Duff, A., Lambrecht, P., Solé, A., Tibosch, M. M., Bergsten Brucefors, A., Yüksel, H., Catastini, P., et al. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-205983 · Cited by 524
Self-citationBrazilian guidelines for the diagnosis and treatment of cystic fibrosis
Athanazio, R. A., Filho, L. V. R. F. D. S., Vergara, A. A., Ribeiro, A. F., Riedi, C. A., Procianoy, E. D. F. A., Adde, F. V., Reis, F. J. C., Ribeiro, J. D., Torres, L. A. G. M. M., et al. (2017) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37562017000000065 · Cited by 252
“These actions are essential, since adequate compliance with the actions inherent to the disease is related to relevant clinical benefits.(239-242)”
BackgroundHilliard, M. E., Hahn, A., Ridge, A. K., Eakin, M. N., & Riekert, K. A. (2014) · JMIR mHealth and uHealth · doi:10.2196/mhealth.3599 · Cited by 139
“The motivation and organizational skills required to consistently follow this demanding regimen can lead to suboptimal CF management [37], which has implications for increased morbidity and health care utilization [38].”
BackgroundSelf-citationMayer-Hamblett, N., Ratjen, F. A., Russell, R., Donaldson, S. H., Riekert, K. A., Sawicki, G. S., Odem‐Davis, K., Young, J., Rosenbluth, D., Taylor‐Cousar, J. L., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00434-9 · Cited by 160
Self-citationLechtzin, N., Mayer-Hamblett, N., West, N. E., Allgood, S., Wilhelm, E., Khan, U., Aitken, M. L., Ramsey, B. W., Boyle, M. P., Mogayzel, P. J., et al. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201610-2172oc · Cited by 127
“In CF, achieving adherence to medications, much less extra home monitoring, can be very challenging when extended to a broader population (28).”
BackgroundElborn, J. S., Bell, S. C., Madge, S. L., Burgel, P.-R., Castellani, C., Conway, S., De Rijcke, K., Dembski, B., Drevinek, P., Heijerman, H. G. M., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00592-2015 · Cited by 120
The psychological burden of cystic fibrosis
Quittner, A. L., Saez-Flores, E., & Barton, J. D. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000244 · Cited by 102
Self-citationCharacterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials
Davies, G., Rowbotham, N. J., Smith, S., Elliot, Z. C., Gathercole, K., Rayner, O., Leighton, P. A., Herbert, S., Duff, A. J., Chandran, S., et al. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.10.025 · Cited by 99
“Our results for time spent on treatment, and number of treatments, are consistent with previously published surveys of treatment burden in CF (6-8).”
ResultAdherence to therapies in cystic fibrosis: a targeted literature review
Narayanan, S., Mainz, J. G., Gala, S., Tabori, H., & Grossoehme, D. H. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1280399 · Cited by 110
Fibrous dysplasia and cemento-ossifying fibroma. A histologic spectrum.
Voytek, T. M., Ro, J. Y., Edeiken, J., & Ayala, A. G. (1995) · PubMed · Cited by 91
Treatment adherence and health outcomes in patients with bronchiectasis
McCullough, A. R., Tunney, M. M., Quittner, A. L., Elborn, J. S., Bradley, J. M., & Hughes, C. M. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-107 · Cited by 87
Self-citationKnudsen, K. B., Pressler, T., Mortensen, L. H., Jarden, M., Skov, M., Quittner, A. L., Katzenstein, T. L., & Boisen, K. A. (2016) · SpringerPlus · doi:10.1186/s40064-016-2862-5 · Cited by 93
“These Danish results are similar to the highest rates reported in TIDES study, with rates of 29 % reported at centers using the CES-D as a screening tool (Quittner et al. 2014b).”
BackgroundResultInfluentialSelf-citationMedication beliefs mediate between depressive symptoms and medication adherence in cystic fibrosis.
Hilliard, M. E., Eakin, M. N., Borrelli, B., Green, A., & Riekert, K. A. (2015) · Health Psychology · doi:10.1037/hea0000136 · Cited by 77
“Furthermore, the cMPR has been found to be associated with CF health outcomes (Eakin et al., 2011) and health care utilization (Quittner et al., 2014), suggesting that it is a valid construct.”
InfluentialSelf-citationGrossoehme, D. H., Szczesniak, R. D., Britton, L., Siracusa, C. M., Quittner, A. L., Chini, B. A., Dimitriou, S. M., & Seid, M. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201408-379oc · Cited by 79
Self-citationParental Depression and Pancreatic Enzymes Adherence in Children With Cystic Fibrosis
Barker, D. H., & Quittner, A. L. (2016) · Pediatrics · doi:10.1542/peds.2015-2296 · Cited by 75
Self-citationStrategies to optimize treatment adherence in adolescent patients with cystic fibrosis
Bishay, L. C., & Sawicki, G. S. (2016) · Adolescent Health Medicine and Therapeutics · doi:10.2147/ahmt.s95637 · Cited by 82
“16 For example, adherence to nutritional treatments (such as vitamins, diet, enzymes) is associated with higher weight and improved nutritional status, which has in turn been shown in childhood to be associated with improved lung function and in turn longer survival.”
Inhaled therapy in cystic fibrosis: agents, devices and regimens
Agent, P., & Parrott, H. (2015) · Breathe · doi:10.1183/20734735.021014 · Cited by 69
“An alternative method is to study prescription collection rates, known as medication possession ratios, and a vast study in the USA assessed 12-month composite medication possession ratios (CMPR) in 3287 patients with CF (aged over 6 years) for a variety of pulmonary medications [48].”
Bilton, D., Pressler, T., Fajac, I., Clancy, J. P., Sands, D., Minic, P. B., Cipolli, M., Galeva, I., Solé, A., Quittner, A. L., et al. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.08.001 · Cited by 68
Self-citationQuality of life and mood in children with cystic fibrosis: Associations with sleep quality
Vandeleur, M., Walter, L. M., Armstrong, D., Robinson, P. J., Nixon, G. M., & Horne, R. S. C. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.11.021 · Cited by 64
“Of note, rates of adherence to treatment in children with CF are already low with a recent study reporting adherence to pulmonary medications at 50% or less, getting worse as children get older [33].”
BackgroundWildman, M. J., O’Cathain, A., Maguire, C., Arden, M. A., Hutchings, M., Bradley, J., Walters, S. J., Whelan, P., Ainsworth, J., Buchan, I., et al. (2022) · Thorax · doi:10.1136/thoraxjnl-2021-217594 · Cited by 54
Lanzkron, S., Sawicki, G. S., Hassell, K. L., Konstan, M. W., Liem, R. I., & McColley, S. A. (2018) · Journal of Clinical and Translational Science · doi:10.1017/cts.2018.338 · Cited by 54
“Adherence rates in CF are clearly suboptimal, and the lowest rates of adherence in CF are among adolescents and young adults [52].”
BackgroundA five-year retrospective analysis of adherence in cystic fibrosis
Shakkottai, A., Kidwell, K., Townsend, M., & Nasr, S. Z. (2015) · Pediatric Pulmonology · doi:10.1002/ppul.23307 · Cited by 50
“There are more CFrelated hospitalizations among individuals with low and moderate adherence.(8) They also incur higher health care costs compared to those with higher adherence.”
BackgroundResultInfluentialOpportunities for cystic fibrosis care teams to support treatment adherence
Riekert, K. A., Eakin, M. N., Bilderback, A. L., Ridge, A. K., & Marshall, B. C. (2014) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2014.10.003 · Cited by 47
Self-citationArden, M. A., Hutchings, M., Whelan, P., Drabble, S. J., Beever, D., Bradley, J. M., Hind, D., Ainsworth, J., Maguire, C., Cantrill, H., et al. (2021) · Pilot and Feasibility Studies · doi:10.1186/s40814-020-00739-2 · Cited by 44
Treatment Preference Among People With Cystic Fibrosis
Cameron, R. A., Daniel Office, Matthews, J., Rowley, M., Abbott, J., Simmonds, N. J., Whitty, J. A., & Carr, S. B. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.07.008 · Cited by 50
Impact of home spirometry on medication adherence among adolescents with cystic fibrosis
Shakkottai, A., Kaciroti, N., Kasmikha, L., & Nasr, S. Z. (2018) · Pediatric Pulmonology · doi:10.1002/ppul.23950 · Cited by 42
“An important risk factor for this reduction in PFT is having frequent pulmonary exacerbations,(13) a factor that has been linked to poor medication adherence.(1,3,4) Poor nutritional status is another risk”
BackgroundResultTackling the increasing complexity of CF care
Sawicki, G. S., & Goss, C. H. (2015) · Pediatric Pulmonology · doi:10.1002/ppul.23244 · Cited by 46
“Additionally, lower composite medication possession ratios were associated with more frequent exacerbations and lower lung function,(15) and a recent analysis identified a connection between poor prescription refill rates and increased cost.(17) Achieving optimal adherence to chronic therapies is multi-factorial, and…”
BackgroundReview: Quality of Life in Children with Non-cystic Fibrosis Bronchiectasis
Nathan, A. M., de Bruyne, J. A., Eg, K. P., & Thavagnanam, S. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00084 · Cited by 47
“J Allergy Clin Immunol (2013) 131(4):1069–74.”
BackgroundInfluentialMcCullough, A. R., Ryan, C. A., Macindoe, C., Yii, N., Bradley, J. M., O'Neill, B. M., Elborn, J. S., & Hughes, C. M. (2016) · Respiratory Medicine · doi:10.1016/j.rmed.2016.05.021 · Cited by 44
Role of habit in treatment adherence among adults with cystic fibrosis
Hoo, Z. H., Gardner, B., Arden, M. A., Waterhouse, S., Walters, S. J., Campbell, M. J., Hind, D., Maguire, C., Dewar, J., & Wildman, M. J. (2019) · Thorax · doi:10.1136/thoraxjnl-2017-211453 · Cited by 40
“Adherence to preventative inhaled treatments is associated with better health outcomes in cystic fibrosis (CF) but adherence levels are generally low.[1] Effective adherence interventions are lacking,[2] and reasons for low adherence are poorly understood.”
Supporting medication adherence for adults with cystic fibrosis: a randomised feasibility study
Hind, D., Drabble, S. J., Arden, M. A., Mandefield, L., Waterhouse, S., Maguire, C., Cantrill, H., Robinson, L., Beever, D., Scott, A. J., et al. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0834-6 · Cited by 40
Verkleij, M., de Winter, D., Hurley, M. A., & Abbott, J. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.02.005 · Cited by 37
“Compared to community samples, the symptoms of anxiety and depression have been shown to be 2-3 times more frequent in pediatric CF patients and their primary caregivers [3,4], with associated negative health outcomes, worse treatment adherence and greater healthcare utilization [5-9].”
A practical approach to reporting treatment abandonment in pediatric chronic conditions
Weaver, M. S., Arora, R. S., Howard, S. C., Salaverria, C. E., Liu, Y., Ribeiro, R. C., & Lam, C. G. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25403 · Cited by 36
Cystic fibrosis patient registries: A valuable source for clinical research
Dasenbrook, E. C., & Sawicki, G. S. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.03.001 · Cited by 36
“Indeed, poor adherence to chronic CF therapies, as defined by medication possession ratios, is well described [43].”
BackgroundCystic Fibrosis Lung Disease Modifiers and Their Relevance in the New Era of Precision Medicine
Sepahzad, A., Morris-Rosendahl, D. J., & Davies, J. C. (2021) · Genes · doi:10.3390/genes12040562 · Cited by 40
Olveira, C., Solé, A., Girón, R. M., Quintana‐Gallego, E., Mondejar, P., Baranda, F., Alvarez, A., Prados, C., Rodríguez-González, J., Labarga, I. H., et al. (2016) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2016.02.002 · Cited by 35
Self-citationImpact of pharmacy services on cystic fibrosis medication adherence
Zobell, J. T., Schwab, E., Collingridge, D. S., Ball, C., Nohavec, R., & Asfour, F. (2017) · Pediatric Pulmonology · doi:10.1002/ppul.23743 · Cited by 36
“Studies have demonstrated that low adherence leads to an increase in hospitalizations and healthcare costs.(9,12,16,20) The cost of medications and healthcare continues to rise and pharmacists must continue to demonstrate their value as part of the CF healthcare team by improving outcomes.”
BackgroundMethodInfluentialGreen, N., Manwani, D. G., Rahim, M. Q., Ireland, K., Sinha, A. A., & Smaldone, A. M. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26161 · Cited by 34
Blackwell, L. S., & Quittner, A. L. (2014) · Pediatric Pulmonology · doi:10.1002/ppul.23091 · Cited by 36
Self-citationCystic Fibrosis Transitions of Care
Okumura, M. J., & Kleinhenz, M. E. (2015) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2015.11.007 · Cited by 36
“Poor adherence leads to increased hospitalizations and higher health care costs as compared with those with high adherence.(33) Numerous barriers to adherence are known: poor understanding of the consequences of nonadherence, depression, social stigma of having a chronic disease, forgetting to take medications, lack o…”
BackgroundGur, M., Nir, V., Teleshov, A., Bar‐Yoseph, R., Manor, E., Diab, G., & Bentur, L. (2016) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x16649532 · Cited by 30
“Moreover, monitoring symptoms and making objective measures, such as spirometry and the 3-Minute Step Test, via telehealth were found to be feasible.(1,18) Fadaizadeh et al.”
BackgroundMethodFriedman, D., Linnemann, R. W., Altstein, L. L., Islam, S., Bach, K., Lamb, C., Volpe, J., Doolittle, C., John, A. S., O’Malley, P. J., et al. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.02.011 · Cited by 33
Eaton, C. K., Eakin, M. N., Coburn, S. S., Pruette, C. S., Brady, T. M., Fivush, B. A., Mendley, S. R., Tuchman, S., & Riekert, K. A. (2018) · Journal of Pediatric Psychology · doi:10.1093/jpepsy/jsy073 · Cited by 34
Self-citationWessels-Bakker, M. J., van de Graaf, E. A., Erp, J. M. K., Heijerman, H. G. M., Cahn, W., & Schappin, R. (2021) · Journal of Clinical Nursing · doi:10.1111/jocn.15931 · Cited by 36
Medication adherence to CFTR modulators in patients with cystic fibrosis: a systematic review
Hansen, C. M. E., Breukelman, A. J., van den Bemt, P. M. L. A., Zwitserloot, A. M., van Dijk, L., & van Boven, J. F. M. (2024) · European Respiratory Review · doi:10.1183/16000617.0060-2024 · Cited by 31
“However, the majority of studies were published prior to the development of the CFTR modulators and therefore focused mostly on nebulisers and other symptomatic therapies [12].”
InfluentialQuittner, A. L., Eakin, M. N., Alpern, A. N., Ridge, A. K., McLean, K. A., Bilderback, A., Criado, K. K., Chung, S.-E., & Riekert, K. A. (2019) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.05.004 · Cited by 27
Self-citationHoo, Z. H., Curley, R., Campbell, M. J., Walters, S. J., Hind, D., & Wildman, M. J. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s105530 · Cited by 27
“2,5,11,12 Therefore, the genotype is useful in supplementing the information provided by pancreatic status in terms of confirming that an individual has a milder phenotype.”
Melani, A. S., & Paleari, D. (2015) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.3109/15412555.2015.1045972 · Cited by 30
“It is well-known that adherence rates are very low in cystic fi brotic patients and worse adherence was associated with poorer clinical outcomes (39).”
BackgroundRouzé, H., Viprey, M., Allemann, S. S., Dima, A. L., Caillet, P., Denis, A., Bourdy, S., Camara, B., Llerena, C., Reix, P., et al. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s211769 · Cited by 33
Promoting emotional wellness in children with CF, part II: Mental health assessment and intervention
Georgiopoulos, A. M., Christon, L., Filigno, S. S., Mueller, A., Prieur, M. G., Boat, T. F., & Smith, B. A. (2021) · Pediatric Pulmonology · doi:10.1002/ppul.24977 · Cited by 33
Pakhale, S. S., Baron, J., Armstrong, M. B., Tasca, G. A., Gaudet, E., Aaron, S. D., Cameron, D. W., & Balfour, L. (2016) · Patient Education and Counseling · doi:10.1016/j.pec.2016.03.023 · Cited by 26
White, H., Shaw, N., Denman, S., Pollard, K., Wynne, S., & Peckham, D. G. (2017) · European Respiratory Journal · doi:10.1183/13993003.00987-2016 · Cited by 25
“associate treatment burden with barriers to adherence,[25,26] but agrees with findings by Quittner et al who reported a positive association between medication regimen complexity and adherence.[9] However their proposal that a more complex regimen may be a proxy for disease severity and a greater willingness to undert…”
BackgroundResultInfluentialClinical communication preferences in cystic fibrosis and strategies to optimize care
Cooley, L., Hudson, J. N., Potter, E., Raymond, K. F., George, C., & Georgiopoulos, A. M. (2020) · Pediatric Pulmonology · doi:10.1002/ppul.24655 · Cited by 25
Song, J. T., Desai, S., Franciosi, A. N., Dagenais, R., & Quon, B. S. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.05.005 · Cited by 24
Tappenden, P., Sadler, S., & Wildman, M. J. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0500-x · Cited by 24
Young, D. C., Autry, E. B., Zobell, J. T., Kormelink, L. N., Homa, K. A., Sabadosa, K. A., Kanga, J. F., Anstead, M., & Kuhn, R. J. (2019) · Pediatric Pulmonology · doi:10.1002/ppul.24348 · Cited by 24
“People with CF can take an average of 10 (±5) medications per day, such as oral antibiotics, aerosolized mucolytic agents, and pancreatic enzymes.(6) Other daily interventions may be nutritional supplements, including CF‐specific vitamins, high‐calorie foods, and enteral feedings.”
Schwarz, C., Schulte-Hubbert, B., Bend, J., Abele‐Horn, M., Baumann, I., Bremer, W., Brunsmann, F., Dieninghoff, D., Eickmeier, O., Ellemunter, H., et al. (2018) · Pneumologie · doi:10.1055/s-0044-100191 · Cited by 29
“[157] Quittner AL, Zhang J, Marynchenko M et al.”
Nicolais, C. J., Bernstein, R. M., Saez-Flores, E., McLean, K. A., Riekert, K. A., & Quittner, A. L. (2019) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-018-9598-z · Cited by 27
“This “combination strategy” should be potentially integrated into interventions that aim to both increase adherence and promote the transition to adult care (Madan, Alpern, & Quittner, 2014).”
BackgroundSelf-citationHoo, Z. H., Boote, J., Wildman, M. J., Campbell, M. J., & Gardner, B. (2017) · Health Psychology and Behavioral Medicine · doi:10.1080/21642850.2017.1338958 · Cited by 21
“High adherence is associated with reduced lung function decline, fewer pulmonary exacerbations and lower treatment costs (Eakin, Bilderback, Boyle, Mogayzel, & Riekert, 2011; Quittner et al., 2014).”
BackgroundReady, Steady, Go – Achieving successful transition in cystic fibrosis
Connett, G. J., & Nagra, A. (2018) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2018.05.007 · Cited by 21
Food insecurity and mental health during the COVID‐19 pandemic in cystic fibrosis households
Lim, J. T., Ly, N. P., Willen, S. M., Iwanaga, K., Gibb, E. R., Chan, M., Church, G. D., Neemuchwala, F., & McGarry, M. E. (2022) · Pediatric Pulmonology · doi:10.1002/ppul.25850 · Cited by 25
“The decreased treatment and medication adherence are concerning as adherence is an important prognostic indicator for likelihood of having a CF‐related hospitalization or ED visit.(31) Mental health worsened in people with CF and their families during the pandemic.”
BackgroundPatient knowledge and pulmonary medication adherence in adult patients with cystic fibrosis
Lin, A. H.-A., Kendrick, J. G., Wilcox, P., & Quon, B. S. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s129088 · Cited by 18
“25 Low socioeconomic status is another significant factor associated with worse adherence to airway clearance therapy in CF 26 and inhaled steroid therapy in asthma 27 but has not been clearly demonstrated with respiratory medications in CF. 28 Due to the anonymous nature of data collection in this study, these variab…”
InfluentialHoo, Z. H., Campbell, M. J., Curley, R., Walters, S. J., & Wildman, M. J. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.10.005 · Cited by 18
Unmet needs in cystic fibrosis: the next steps in improving outcomes
West, N. E., & Flume, P. A. (2018) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2018.1483723 · Cited by 22
“medications is associated with increased hospitalizations [37].”
Understanding the expanding role of pharmacy services in outpatient cystic fibrosis care
Zobell, J. T., Moss, J., Heuser, S. M., Roe, L., & Young, D. C. (2021) · Pediatric Pulmonology · doi:10.1002/ppul.25283 · Cited by 19
Investigating the effects of long-term dornase alfa use on lung function using registry data
Newsome, S., Daniel, R., Carr, S. B., Bilton, D., & Keogh, R. H. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2018.08.004 · Cited by 19
“It is known to be particularly hard to measure adherence levels, but previous studies have estimated that average adherence levels to nebulised therapies, such as DNase, may range between 60% and 70% [25,26].”
Jackson, A. D., Kirwan, L., Gibney, S., Jeleniewska, P., Fletcher, G., & Doyle, G. (2019) · European Journal of Public Health · doi:10.1093/eurpub/ckz148 · Cited by 27
Zobell, J. T., Moss, J., Heuser, S. M., & Asfour, F. (2020) · Pediatric Pulmonology · doi:10.1002/ppul.25050 · Cited by 18
Eaton, C. K., McWilliams, E., Yablon, D., Kesim, I., Ge, R., MIRUS, K. A., Sconiers, T., Donkoh, A., Lawrence, M., George, C., et al. (2024) · JMIR mhealth and uhealth · doi:10.2196/49024 · Cited by 32
“…from the extant scientific literature to inform the development of multicomponent behavioral mHealth interventions tailored for a patient population that may be smaller and with less existing research, yet has significant self-management needs warranting further research, such as CF [9,10,31,32].”
BackgroundSelf-citationSawyer, A., Lewthwaite, H., Gucciardi, D. F., Hill, K., JENKINS, S. C., & Cavalheri, V. (2019) · Internal Medicine Journal · doi:10.1111/imj.14141 · Cited by 22
Real-World Adherence Among Adults With Cystic Fibrosis Is Low
Hoo, Z. H., Totton, N., Waterhouse, S., Lewis, J., Girling, C., Bradburn, M. J., Arden, M. A., Whelan, P., Ainsworth, J. D., Dawson, S., et al. (2021) · CHEST Journal · doi:10.1016/j.chest.2021.06.039 · Cited by 21
The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis
Chin, M., Aaron, S. D., & Bell, S. C. (2017) · La Presse Médicale · doi:10.1016/j.lpm.2016.11.030 · Cited by 20
Friedman, D., Linnemann, R. W., Altstein, L. L., Georgiopoulos, A. M., Islam, S., Bach, K., John, A. S., Fracchia, M. S., Neuringer, I. P., Lapey, A., et al. (2019) · Pediatric Pulmonology · doi:10.1002/ppul.24311 · Cited by 21
The pharmacist's role in supporting people living with cystic fibrosis
Abraham, O., Li, J. S., Monangai, K. E., Feathers, A. M., & Weiner, D. E. (2018) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2018.01.006 · Cited by 21
Outcome evaluation of a pharmacy‐based therapy management program for patients with cystic fibrosis
Kirkham, H. S., Staskon, F. C., Hira, N., McLane, D., Kilgore, K. M., Parente, A., Kim, S., & Sawicki, G. S. (2018) · Pediatric Pulmonology · doi:10.1002/ppul.23978 · Cited by 18
New and Emerging Treatments for Cystic Fibrosis
Barry, P. J., & Jones, A. M. (2015) · Drugs · doi:10.1007/s40265-015-0424-8 · Cited by 19
The Use of Home Spirometry in Pediatric Cystic Fibrosis Patients: Results of a Feasibility Study
Shakkottai, A., & Nasr, S. Z. (2017) · Global Pediatric Health · doi:10.1177/2333794x17690315 · Cited by 16
Aztreonam Lysine Inhalation Solution in Cystic Fibrosis
Elson, E. C., Mermis, J. D., Polineni, D., & Oermann, C. M. (2019) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.1177/1179548419842822 · Cited by 18
Eaton, C. K., Beachy, S., McLean, K. A., Nicolais, C. J., Bernstein, R. M., Saez-Flores, E., Quittner, A. L., & Riekert, K. A. (2020) · Patient Education and Counseling · doi:10.1016/j.pec.2020.02.025 · Cited by 18
Self-citationMacdonald, M., Martin‐Misener, R., Helwig, M., Smith, L. J., Godfrey, C. M., Curran, J., & Murphy, A. L. (2016) · The JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2016-002362 · Cited by 19
“lost productivity of patients and families).(36,38) A recent longitudinal retrospective pharmacy medication review of patients aged six and older measured adherence to respiratory medication to predict infection requiring IV antimicrobials.”
BackgroundSmaldone, A. M., Manwani, D. G., Aygün, B., Smith‐Whitley, K., Jia, H., Bruzzese, J., Findley, S. E., Massei, J. R., & Green, N. (2019) · BMC Pediatrics · doi:10.1186/s12887-019-1746-6 · Cited by 16
Telemedicine in cystic fibrosis
Desimone, M. E., Sherwood, J. S., Soltman, S., & Moran, A. (2021) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2021.100270 · Cited by 16
“CF found that adherence was 48% and decreased with age, especially during the adolescent time period [96].”
BackgroundDawson, S., Girling, C.-J., Cowap, L., & Clark-Carter, D. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013766.pub2 · Cited by 14
Living with cystic fibrosis – a qualitative study of a life coaching intervention
Knudsen, K. B., Boisen, K. A., Katzenstein, T. L., Mortensen, L. H., Pressler, T., Skov, M., & Jarden, M. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s159306 · Cited by 14
“Several studies have found that people with CF have low adherence to treatment and an increased prevalence of anxiety and depression.(3,5,6) Psychological health problems are burdensome in themselves; besides, they may negatively affect quality of life, and furthermore reduce adherence to treatment.”
BackgroundCoach to cope: feasibility of a life coaching program for young adults with cystic fibrosis
Knudsen, K. B., Pressler, T., Mortensen, L. H., Jarden, M., Boisen, K. A., Skov, M., Quittner, A. L., & Katzenstein, T. L. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s141267 · Cited by 15
Self-citationTrapnell, B. C., Su, C., Khurmi, R., Bodhani, A. R., Kapoor, M., & Haupt, M. E. (2020) · Chronic Respiratory Disease · doi:10.1177/1479973119900612 · Cited by 15
“However, a recent study reported that adherence rates to pulmonary medications in CF were greatest in patients aged 6 to 10 years (59%) and decreased to approximately 40% to 50% in older children and adults.(11) Thus, in patients with CF, if PERT adherence is similar to adherence to pulmonary medications, we would not…”
BackgroundMueller, A., Georgiopoulos, A. M., Reno, K., Roach, C. M., Kvam, C. M., Quittner, A. L., Lomas, P., Smith, B. A., & Filigno, S. S. (2020) · Health & Social Work · doi:10.1093/hsw/hlaa009 · Cited by 17
Self-citationHind, D., Drabble, S. J., Arden, M. A., Mandefield, L., Waterhouse, S., Maguire, C., Cantrill, H., Robinson, L., Beever, D., Scott, A. J., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-039089 · Cited by 18
Grafton, K., Wheldon, C., Stiger, R. J., Robbins, N., Baker, C., & Jones, U. (2022) · Journal of the Association of Chartered Physiotherapists in Respiratory Care · doi:10.56792/lmmq6301 · Cited by 13
Connett, G. J., Maguire, S., Larcombe, T., Scanlan, N., Shinde, S. S., Muthukumarana, T., Bevan, A., Keogh, R. H., & Legg, J. P. (2024) · Respiratory Medicine · doi:10.1016/j.rmed.2024.107882 · Cited by 18
Development and validation of CF-Medication Beliefs Questionnaire: A mixed-methods approach
Eakin, M. N., Chung, S.-E., Hoehn, J., Borrelli, B., Rand-Giovannetti, D., & Riekert, K. A. (2017) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.05.001 · Cited by 16
“-Medic poor adherence likely contributes to poor health outcomes, including increased risk of exacerbations and lung function decline, and higher healthcare costs [3,4].”
BackgroundSelf-citationDrug interactions and treatment burden as survival improves
Nichols, D. P., Kuk, K. N., & Nick, J. A. (2015) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000212 · Cited by 15
Parent knowledge of disease management in cystic fibrosis: Assessing behavioral treatment management
Nicolais, C. J., Bernstein, R. M., Riekert, K. A., & Quittner, A. L. (2017) · Pediatric Pulmonology · doi:10.1002/ppul.23916 · Cited by 14
“50%.(14) Thus, parents play a critical role in managing and “modeling” their adolescents’ treatment-related behaviors (eg, set-up and cleaning; reminders)(8) and need accurate knowledge about them and their effects.”
BackgroundSelf-citationReevaluating approaches to cystic fibrosis pulmonary exacerbations
Schechter, M. S. (2018) · Pediatric Pulmonology · doi:10.1002/ppul.24125 · Cited by 48
Hoo, Z. H., Wildman, M. J., Campbell, M. J., Walters, S. J., & Gardner, B. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s186417 · Cited by 15
Chang, H., Kan, H. J., Shermock, K. M., Alexander, G. C., Weiner, J. P., & Kharrazi, H. H. K. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.10.1282 · Cited by 14
“and more hospitalizations.(5) Another study found that higher medication adherence significantly reduces annual costs for secondary prevention of coronary artery disease (between $294 and $868 per patient(6)).”
BackgroundLandau, E., Verkleij, M., Graziano, S., Quittner, A. L., Georgiopoulos, A. M., Smith, B. A., Schechter, M. S., & Abbott, J. (2022) · Respiratory Medicine · doi:10.1016/j.rmed.2022.106955 · Cited by 13
Self-citation
Metadata
- Authors
- Quittner, A. L., Zhang, J., Marynchenko, M., Chopra, P. A., Signorovitch, J., Yushkina, Y., & Riekert, K. A.
- Affiliations
- University of Miami (US)
- Novartis (United States) (US)
- Analysis Group (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- Quittner, Alexandra L.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 146
- Issue
- 1
- Pages
- 142-151
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2070450626
- Cited by
- 250
- References
- 28
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 11 · 2023: 24 · 2022: 28 · 2021: 20 · 2020: 29 · 2019: 23 · 2018: 20 · 2017: 28 · 2016: 15 · 2015: 22 · 2014: 6
- FWCI
- 24.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- CHEST Journal (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
- Keywords
- cystic fibrosis, medication adherence, medication possession ratio, health care utilization, hospitalization, health care costs, outpatient visits, emergency department visits, age, privately insured patients
- MeSH terms
- Adolescent, Adult, Child, Cystic Fibrosis, Delivery of Health Care, Female, Follow-Up Studies, Humans, Immunosuppressive Agents, Male, Patient Compliance, Retrospective Studies, Health Care Costs, Disease Management, Medication Adherence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.